BioSpace News Archive

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the H.C. Wainwright 4 th Annual NASH Investor Conference on Monday, October 5, 2020 at 11:30 AM ET. The live and archived webcast of the presentation wi

Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, as well as various health and well-being-focused plant-based products in China, announced today its financial results for the fiscal year ended June 30, 2020. Mr. Guocong Zhou, Chief Executive Officer of Shineco, commented, “In fiscal 2020, we achieved a revenue of USD23.68 million and a net loss

The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies ( #NCCNhem20 ) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online Thursday, October 8, 2020 – Saturday, October 10, 2020 .

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced preliminary six-month results from the open-label extension (OLE) portion of PaTH Forward, a global phase 2 trial evaluating the safety,

Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ), announces that the Company will be relying on the temporary 45 day extension to the filing deadline of its financial statements and management’s discussion and analysis (“MD&A”) for the quarter ended June 30, 2020 granted by the Alberta Securities Commission (“ASC”) in response to unprecedented challenges resulting from COVID-19. As per Nati

The U.S. Food and Drug Administration issued the final guidance, “Breast Implants - Certain Labeling Recommendations to Improve Patient Communication,” as part of the agency’s effort to help improve the information available to patients and health care professionals about the risks of breast implants.

LabCorp (NYSE: LH) will release its third quarter of 2020 financial results before the market opens on Tuesday, Oct. 27, 2020, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website . Interested parties can access the conference call by dialing 1-

Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the third quarter ended September 30, 2020. Molina Healthcare will issue its earnings release for the third quarter of 2020 after the market closes on Wednesday, October 28, 2020, and will host a conference call and webcast to discuss the earnings release on Thursday, October 29, 2020, at 8:00 a.m. Eastern Time. To access this interactive teleco

Shape Therapeutics, Inc. (ShapeTX), a pre-clinical stage company with an industry-leading RNA targeting technology platform, announced today that Francois Vigneault, PhD., President & Chief Executive Officer, will highlight advances in their RNAfix™ ADAR editing platform, including data that demonstrates RNA editing up to ~90% in genes implicated in Parkinson’s disease. The presentation will be on Friday, October 2, 2020 at

Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were app